Clinical TrialsThe Phase 3 SELVA trial has exceeded the enrollment target of 40 patients, demonstrating a strong interest in the program by the community.
Financial PerformanceThe company has $75.6M cash which provides runway through the second half of 2027, covering multiple trials and product developments.
Product DevelopmentQTORIN rapamycin was exclusively developed for a serious rare disease where nothing has been approved for nearly 44K diagnosed microcystic LM patients.